Quinn Opportunity Partners LLC Purchases Shares of 20,000 Janux Therapeutics, Inc. (NASDAQ:JANX)

Quinn Opportunity Partners LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, HoldingsChannel reports. The firm acquired 20,000 shares of the company’s stock, valued at approximately $1,071,000.

A number of other large investors also recently modified their holdings of JANX. Russell Investments Group Ltd. boosted its position in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the fourth quarter worth about $139,000. Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $159,000. Chicago Capital LLC acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $230,000. Finally, Cerity Partners LLC purchased a new position in Janux Therapeutics in the 4th quarter worth approximately $239,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Up 7.2 %

NASDAQ:JANX opened at $28.80 on Friday. Janux Therapeutics, Inc. has a 52 week low of $22.52 and a 52 week high of $71.71. The company has a market cap of $1.70 billion, a PE ratio of -24.62 and a beta of 3.27. The business’s 50 day moving average is $31.72 and its two-hundred day moving average is $44.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

JANX has been the topic of a number of analyst reports. Scotiabank dropped their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reissued an “outperform” rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $92.44.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the purchase, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.